FDA Approves Gazyva as First Drug for Primary Membranous Nephropathy
The FDA has approved Genentech's Gazyva for adults with primary membranous nephropathy, a rare autoimmune kidney disease with no previously approved drug. In a 142-patient trial, complete remission at two years was far more common than with tacrolimus, an off-label standard option.